| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.05B | 3.65B | 2.48B | 3.01B | 2.78B | 3.07B |
| Gross Profit | 2.13B | 2.29B | 1.03B | 1.67B | 1.54B | 1.71B |
| EBITDA | 577.27M | 497.98M | 536.39M | 488.91M | -497.06M | 684.33M |
| Net Income | 425.26M | 386.00M | 396.19M | 350.11M | -673.38M | 556.62M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 10.26B | 8.80B | 7.93B | 7.42B | 7.90B |
| Cash, Cash Equivalents and Short-Term Investments | 888.99M | 888.99M | 774.10M | 379.90M | 41.68M | 292.11M |
| Total Debt | 0.00 | 1.23B | 1.10B | 1.05B | 929.59M | 965.67M |
| Total Liabilities | -6.44B | 3.82B | 2.70B | 2.20B | 2.00B | 1.76B |
| Stockholders Equity | 6.44B | 6.44B | 6.10B | 5.73B | 5.42B | 6.13B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 96.61M | 478.18M | 358.18M | -39.70M | -104.86M |
| Operating Cash Flow | 0.00 | 175.81M | 745.94M | 383.67M | 170.46M | 11.13M |
| Investing Cash Flow | 0.00 | -39.62M | -274.01M | -28.84M | -198.66M | -102.82M |
| Financing Cash Flow | 0.00 | -21.30M | -77.78M | -16.68M | -222.27M | 164.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹5.16B | 14.04 | ― | 0.30% | 19.25% | 67.58% | |
65 Neutral | ₹3.25B | 8.02 | ― | 1.19% | 18.61% | 4.02% | |
64 Neutral | ₹4.18B | 15.42 | ― | ― | ― | ― | |
63 Neutral | ₹3.64B | 13.77 | ― | ― | 8.73% | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
Nath Bio-Genes (India) Ltd. has submitted a compliance certificate for the quarter ending September 30, 2025, in accordance with SEBI (Depositories and Participants) Regulations, 2018. This submission, confirmed by their Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd., ensures that all securities received for dematerialization have been processed and listed appropriately, maintaining regulatory compliance and transparency for stakeholders.